![](https://www.ontario.ca/misc/message-24-info.png)
Important: This version of the e-Laws website will be upgraded to a new version in the coming weeks.
You can try the beta version of the new e-Laws at ontario.ca/laws-beta.
![](/sites/all/themes/ontario/images/ontario-black@2x.png)
O. Reg. 644/05: GENERAL
filed December 9, 2005 under Drug Interchangeability and Dispensing Fee Act, R.S.O. 1990, c. P.23
Skip to contentontario regulation 644/05
made under the
drug interchangeability and dispensing fee act
Made: December 7, 2005
Filed: December 9, 2005
Published on e-Laws: December 12, 2005
Printed in The Ontario Gazette: December 24, 2005
Amending Reg. 935 of R.R.O. 1990
(General)
1. Section 1 of Regulation 935 of the Revised Regulations of Ontario, 1990 is amended by adding the following subsections:
(1.1) Amendments to the Formulary dated January 12, 2006, are deemed to be included in the definition of “Formulary” for the purposes of this Regulation.
(1.2) For the purposes of this Regulation, items 17 and 18 of Part III of the Formulary shall be read as follows:
VORICONAZOLE
17 |
50mg Tab |
|
|
11.8800 |
|
02256460 |
Vfend |
PFI |
11.8800 |
18 |
200mg Tab |
|
|
47.5000 |
|
02256479 |
Vfend |
PFI |
47.5000 |
|
Reason for Use Code |
Clinical Criteria |
||
|
399 |
Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole. The first prescription must be written by a physician based at the hospital where the patient was hospitalized. Note: Limited to 3 months of reimbursement. LU Authorization Period: 1 year. |
2. Clause 6 (1) (b) of the Regulation is amended by striking out “Canadian Coordinating Office of Health Technology Assessment” wherever it appears and substituting in each case “Canadian Coordinating Office for Health Technology Assessment.”
3. This Regulation comes into force on January 12, 2006.